Zephyr AI

On this Veterans Day, we pause to recognize the incredible courage, sacrifice, and unwavering commitment of the individuals who have served our country. Their selflessness has shaped the freedoms we hold dear, and their commitment continues to inspire us all. To all veterans—Thank you for your bravery, resilience, and service. We honor you today and every day.

As we recognize #LungCancerAwarenessMonth in November, it is crucial for us to stay informed about the latest facts surrounding this critical health challenge: ?? Lung cancer is by far the leading cause of cancer death in the US, accounting for about 1 in 5 of all cancer deaths. (American Cancer Society). ?? While lung cancer incidence is decreasing, it continues to be one of the most commonly diagnosed cancers, with about 235,000 new cases diagnosed this year alone. (American Cancer Society). ?? Lung cancer screening can save lives. Early detection is critical for improving survival rates, and screening provides an opportunity to catch lung cancer before symptoms even appear. Learn more about lung cancer screening through The American Lung Cancer Screening Initiative! We advocate for greater access to lung cancer screening and resources for cancer prevention. Our focus remains on advancing cutting-edge research and harnessing technological innovation to propel lung cancer precision medicine into a new era. Through these efforts, we aim to ensure that the latest advancements in treatment and cures are accessible to all individuals affected by this disease.

Join our Chief Scientific Officer, Rachael Brake as she attends this year’s RAS-Targeted Drug Development Summit, delving into the forefront of drug development targeting the Renin-Angiotensin System (RAS). We will be there to engage in insightful discussions and explore the latest trends and technologies reshaping the industry. If you’re attending, don’t miss the opportunity to connect with Rachael and share perspectives on the future of RAS-targeted therapies. Looking forward to the next three days filled of discovery, collaboration, and growth. See you there! #RASDrugDevelopment #PharmaResearch #InnovativeMedicine

On this day, we reflect on the lives lost and the profound impact of September 11, 2001. We honor the bravery and sacrifice of those who have fought for our freedom and who continue to inspire us. Let us #NeverForget.

We’re headed to Barcelona, Spain! ESMO - European Society for Medical Oncology will be the perfect setting to tackle the intricacies of delivering cutting-edge cancer therapies. We’re excited for this invaluable opportunity to stay ahead of emerging trends, expand our knowledge, and foster meaningful connections within the oncology community. If you’re attending, connect with our Chief Scientific Officer, Rachael Brake. Let’s drive the future of oncology together! See you at #ESMO24 !

As we celebrate Labor Day, we take a moment to honor the remarkable dedication of our #team and the entire workforce that drives progress. At Zephyr AI, our #mission to advance patient treatments is fueled by the passion and hard work of our exceptional team members. Your tireless efforts are paving the way for groundbreaking discoveries. ?? #LaborDay2024

Are you ready for World CDx? We are looking forward to engaging with leading experts and innovators in precision medicine and drug development. With four full days of panels and networking, this will be a fantastic opportunity to exchange ideas, explore the latest advancements, and strengthen our commitment to transforming patient care through cutting-edge solutions. If you’re attending, connect with our Senior Director of Business Development, Bill Keating! See you there! #WorldCDx #biotechnology #precisionmedicine #drugdevelopment

Wishing you a safe and happy Fourth of July! ????

At Zephyr AI, our mission is clear: to expand the horizons of precision medicine. We champion the belief that treatments should be finely tuned to every individual. Through our cutting-edge algorithms, we sift through extensive data ranging from genomic profiles to patient records, delivering tailored insights. Our Chief Technology Officer, Jeff Sherman sits down with Virginia Business to discuss our most recent funding and how we are further pioneering advancements in #precisionmedicine. Read more about their conversation below

?? There is an urgent unmet need for improved PARPi biomarkers, particularly for patients who fail multiple lines of therapy. We’re excited by the prospect of pairing our technology with a second generation PARPi to expand the zone of sensitivity and thus the patients who can benefit from these treatments. ?? Join our Principal Research Scientist, Emily Vucic at American Society of Clinical Oncology (ASCO) to learn more about how we are introducing a AI-first composite biomarkers as a next generation tool for clinical development. Learn more: https://bit.ly/3x8P3FR ?? And feel free to explore our ASCO poster for an in-depth view of this latest research, alongside additional company information: https://bit.ly/4c0P3GS #OvarianCancer #Research #PARPInhibitors #ASCO2024